Економски резултати

Restrictive blood transfusion practices are associated with improved patient outcomes. (отвара нови прозор)

Goodnough LT, Maggio P, Hadhazy E, Shieh L, Hernandez-Boussard T, Khari P, Shah N.

Извор‎: Transfusion 2014;54(10 Pt 2):2753-9.

Индекс‎: PubMed 24995770

DOI‎: 10.1111/trf.12723

https://www.ncbi.nlm.nih.gov/pubmed/24995770 (отвара нови прозор)

Improved outcomes and reduced costs associated with a health-system-wide patient blood management program: a retrospective observational study in four major adult tertiary-care hospitals. (отвара нови прозор)

Leahy MF, Hofmann A, Towler S, Trentino KM, Burrows SA, Swain SG, Hamdorf J, Gallagher T, Koay A, Geelhoed GC, Farmer SL.

Извор‎: Transfusion 2017;57(6):1347-58.

Индекс‎: PubMed 28150313

DOI‎: 10.1111/trf.14006

https://www.ncbi.nlm.nih.gov/pubmed/28150313 (отвара нови прозор)

Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients. (отвара нови прозор)

MacLaren R, Sullivan PW.

Извор‎: Value Health 2005;8(2):105-16.

Индекс‎: PubMed 15804319

DOI‎: 10.1111/j.1524-4733.2005.04006.x

https://www.ncbi.nlm.nih.gov/pubmed/15804319 (отвара нови прозор)

Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (отвара нови прозор)

Mehra T, Seifert B, Bravo-Reiter S, Wanner G, Dutkowski P, Holubec T, Moos RM, Volbracht J, Manz MG, Spahn DR

Извор‎: Transfusion 2015;55(12):2807-15.

Индекс‎: PubMed 26264557

DOI‎: 10.1111/trf.13260

https://www.ncbi.nlm.nih.gov/pubmed/26264557 (отвара нови прозор)

Trauma-induced coagulopathy: impact of the early coagulation support protocol on blood product consumption, mortality and costs. (отвара нови прозор)

Nardi G, Agostini V, Rondinelli B, Russo E, Bastianini B, Bini G, Bulgarelli S, Cingolani E, Donato A, Gambale G, Ranaldi G

Извор‎: Crit Care 2015;19:83.

Индекс‎: PubMed 25880548

DOI‎: 10.1186/s13054-015-0817-9

https://www.ncbi.nlm.nih.gov/pubmed/25880548 (отвара нови прозор)

The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. (отвара нови прозор)

Roberts I, Shakur H, Coats T, Hunt B, Balogun E, Barnetson L, Cook L, Kawahara T, Perel P, Prieto-Merino D, Ramos M, Cairns J, Guerriero C.

Извор‎: Health Technol Assess 2013;17(10):1-79.

Индекс‎: PubMed 23477634

DOI‎: 10.3310/hta17100

https://www.ncbi.nlm.nih.gov/pubmed/23477634 (отвара нови прозор)

Reversal of coagulopathy in critically ill patients with traumatic brain injury: recombinant factor VIIa is more cost-effective than plasma. (отвара нови прозор)

Stein DM, Dutton RP, Kramer ME, Scalea TM.

Извор‎: J Trauma 2009;66(1):63-72.

Индекс‎: PubMed 19131807

DOI‎: 10.1097/TA.0b013e318191bc8a

https://www.ncbi.nlm.nih.gov/pubmed/19131807 (отвара нови прозор)

Effect of a restrictive transfusion strategy on transfusion-attributable severe acute complications and costs in the US ICUs: a model simulation. (отвара нови прозор)

Zilberberg MD, Shorr AF.

Извор‎: BMC Health Serv Res 2007;7:138.

Индекс‎: PubMed 17764560

DOI‎: 10.1186/1472-6963-7-138

https://www.ncbi.nlm.nih.gov/pubmed/17764560 (отвара нови прозор)

ИНТЕНЗИВНА НЕГА

Економски резултати

српски (ћирилица)

Економски резултати

https://assetsnffrgf-a.akamaihd.net/assets/ct/d8f8c0370e/images/syn_placeholder_sqr.png

Restrictive blood transfusion practices are associated with improved patient outcomes. (отвара нови прозор)

Improved outcomes and reduced costs associated with a health-system-wide patient blood management program: a retrospective observational study in four major adult tertiary-care hospitals. (отвара нови прозор)

Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients. (отвара нови прозор)

Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (отвара нови прозор)

Trauma-induced coagulopathy: impact of the early coagulation support protocol on blood product consumption, mortality and costs. (отвара нови прозор)

The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. (отвара нови прозор)

Reversal of coagulopathy in critically ill patients with traumatic brain injury: recombinant factor VIIa is more cost-effective than plasma. (отвара нови прозор)

Effect of a restrictive transfusion strategy on transfusion-attributable severe acute complications and costs in the US ICUs: a model simulation. (отвара нови прозор)

Контакт с локалним представницима (ООБ)

Медицинске информације

Филмови

Економски резултати

Изабери језик

Подели